SEC Form 4 · accession 0001214659-19-001445
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce L A Carter
Director
Period of report
Feb 20, 2019
Accepted (ET)
Feb 22, 2019 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 20, 2019 | M | 3,000 | $6.78 | A | 3,000 | D | |
| Common StockF2 | Feb 20, 2019 | S | 900 | $72.50 | D | 2,100 | D | |
| Common StockF3 | Feb 20, 2019 | S | 1,000 | $73.789 | D | 1,100 | D | |
| Common StockF4 | Feb 20, 2019 | S | 1,100 | $74.4382 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $6.78 | Feb 20, 2019 | M | 3,000 | D | — | Sep 26, 2026 | Common Stock | 3,000 | 22,000 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $71.82 to $72.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $73.13 to $74.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $74.17 to $74.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant.